<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: strict governmental controls on", fill: "#002e63"},
{source: "4: strict governmental controls on", target: "4: development", fill: "#002e63"},
{source: "4: development", target: "4: Contents ", fill: "#002e63"},
{source: "4: Contents ", target: "4: manufacture", fill: "#002e63"},
{source: "4: manufacture", target: "4: labeling distribution", fill: "#002e63"},
{source: "4: strict governmental controls on", target: "8: These ", fill: "#996515"},
{source: "8: These ", target: "8: clinical data", fill: "#996515"},
{source: "8: clinical data", target: "8: significant", fill: "#996515"},
{source: "8: These ", target: "12: span increases", fill: "#00008b"},
{source: "12: span increases", target: "12: new products as", fill: "#00008b"},
{source: "12: new products as", target: "12: selling them", fill: "#00008b"},
{source: "12: selling them", target: "12: United States ", fill: "#00008b"},
{source: "12: span increases", target: "41: incur significant costs from", fill: "#321414"},
{source: "41: incur significant costs from", target: "41: development", fill: "#321414"},
{source: "41: development", target: "41: activities", fill: "#321414"},
{source: "41: incur significant costs from", target: "55: restructure", fill: "#556b2f"},
{source: "55: restructure", target: "55: consolidate various aspects", fill: "#556b2f"},
{source: "55: consolidate various aspects", target: "55: operations", fill: "#556b2f"},
{source: "55: operations", target: "55: cost savings", fill: "#556b2f"},
{source: "55: cost savings", target: "55: efficiencies", fill: "#556b2f"},
{source: "55: restructure", target: "START_HERE", fill: "#556b2f"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Democratic_Party_(United_States)">Democratic Party (United States)</a></td>
      <td>The Democratic Party is one of the two major contemporary political parties in the United States. It was founded in 1828 by supporters of Andrew Jackson, making it the world's oldest active political party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ORASURE TECHNOLOGIES INC      ITEM 1A    Risk Factors          The following is a discussion of <font color="blue">certain <font color="blue">significant</font> risk factors</font> that could     <font color="blue">potentially negatively impact</font> our financial condition, performance and     prospects</td>
    </tr>
    <tr>
      <td>Many of our proposed and <font color="blue">existing products</font> are subject to regulation by the     FDA and other <font color="blue"><font color="blue">government</font>al</font> or <font color="blue">public health agencies</font></td>
    </tr>
    <tr>
      <td>In particular, we are     subject to strict <font color="blue"><font color="blue">government</font>al</font> controls on the <font color="blue">development</font>,                                           18     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font><font color="blue">manufacture</font>,  labeling, distribution and marketing of our products</td>
    </tr>
    <tr>
      <td>In     addition, we are often required to obtain approval or <font color="blue">registration with</font>     <font color="blue">foreign <font color="blue">government</font>s</font> or <font color="blue">regulatory bodies</font> before we can import and sell our     products in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>The process of obtaining required approvals or clearances from <font color="blue"><font color="blue">government</font>al</font>     or  <font color="blue">public health agencies</font> can <font color="blue">involve lengthy</font> and <font color="blue">detailed <font color="blue">laboratory</font></font>     testing,  human clinical trials, sampling <font color="blue">activities</font> and other costly,     time-consuming procedures</td>
    </tr>
    <tr>
      <td>For example, during 2004, we received several FDA     approvals  for  our OraQuick^® ADVANCE^^™ rapid HIV-1/2 <font color="blue">antibody test</font>,     including  approval  for  use of the <font color="blue">test on oral fluid samples</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>approvals required the submission of <font color="blue">clinical data</font> and required <font color="blue">significant</font>     time  to  obtain</td>
    </tr>
    <tr>
      <td>The submission of an <font color="blue">application</font> to the FDA or other     <font color="blue">regulatory authority</font> does not guarantee that an approval or clearance to     market the <font color="blue">product will</font> be received</td>
    </tr>
    <tr>
      <td>Each <font color="blue">authority may impose</font> its own     <font color="blue">requirements</font> and delay or refuse to <font color="blue">grant approval</font> or clearance, even though     a product has <font color="blue">been approved</font> in another country or by another agency</td>
    </tr>
    <tr>
      <td>This time <font color="blue">span increases</font> our costs to develop <font color="blue"><font color="blue">new products</font> as</font>     well as the risk that we will not succeed in introducing or <font color="blue">selling them</font> in     the <font color="blue"><font color="blue">United States</font> </font>or other countries</td>
    </tr>
    <tr>
      <td>Newly promulgated or changed <font color="blue"><font color="blue">regulations</font> could also</font> require us to undergo     <font color="blue"><font color="blue">additional</font> trials</font> or procedures, or could make it impractical or impossible     for us to market our products for <font color="blue">certain uses</font>, in <font color="blue">certain markets</font>, or at     all</td>
    </tr>
    <tr>
      <td>For example, during 2004 the Substance Abuse and Mental Health Services     Administration (“SAMHSA”), which is part of the US Department of Health     and Human Services, <font color="blue">issued proposed <font color="blue">regulations</font></font> for the use of oral fluid     <font color="blue">drug testing</font> for <font color="blue">federal workers</font></td>
    </tr>
    <tr>
      <td><font color="blue">The SAMHSA </font><font color="blue">regulations</font>, when issued in     final form, <font color="blue">could permit us</font> to market and sell our <font color="blue">oral fluid drug tests</font> for     use with <font color="blue">federal workers</font> only if <font color="blue">certain <font color="blue">modifications</font></font> are made to our     products</td>
    </tr>
    <tr>
      <td>If  we  are  unable  to make these <font color="blue">modifications</font>, or if the     <font color="blue">modifications</font> require <font color="blue">significant</font> time to develop, our ability to sell our     oral  fluid  <font color="blue">drug testing</font> products in that <font color="blue">market could</font> be limited</td>
    </tr>
    <tr>
      <td>In     addition, the extent to which the final SAMHSA <font color="blue">regulations</font> permit the sale     of our <font color="blue">oral fluid drug tests</font> for use with <font color="blue">federal workers</font> may influence     <font color="blue">whether customers</font> in the workplace, criminal justice or other unregulated     <font color="blue">markets use</font> our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulations</font> in some states <font color="blue">may restrict</font> our ability to <font color="blue">sell products</font> in     those states</td>
    </tr>
    <tr>
      <td>For example, certain states restrict or do not allow the     testing of oral fluid for drugs of abuse or the rapid, point-of-care testing     for HIV While we intend to work with state <font color="blue">legislators</font> and <font color="blue">regulators</font> to     remove or modify any applicable restrictions, there is no guarantee we will     be successful in these efforts</td>
    </tr>
    <tr>
      <td>In addition, all in <font color="blue">vitro <font color="blue">diagnostic</font> products</font> that are to be sold in the     European Union (“EU”) must bear the CE mark <font color="blue">indicating conformance with</font> the     essential <font color="blue">requirements</font> of the In Vitro Diagnostic Directive, or IVDD We are     not permitted to sell our products in the EU without a CE mark, <font color="blue">which could</font>     lead to the <font color="blue">termination</font> of <font color="blue">strategic alliances</font> and <font color="blue"><font color="blue">agreement</font>s</font> for sales of     those products in the EU We have obtained the CE mark for several of our     <font color="blue">existing products</font>, and we intend to CE mark certain of our <font color="blue">future products</font>     and are not aware of any material reason why we will be unable to do so</td>
    </tr>
    <tr>
      <td>However, there can be no assurance that <font color="blue">compliance with</font> all provisions of     the IVDD will be <font color="blue"><font color="blue">demonstrate</font>d</font> and the CE mark will be obtained for all     products that we desire to sell in the EU         Failure to Comply With FDA or Other <font color="blue">Regulatory </font>Requirements May Require Us     to Suspend Production of Our Products or Institute a Recall Which Could     Result in Higher Costs and a Loss of Revenues</td>
    </tr>
    <tr>
      <td>We can <font color="blue">manufacture</font> and sell many of our products, both in the <font color="blue"><font color="blue">United States</font> </font>    and  <font color="blue"><font color="blue">international</font>ly</font>, only if we comply with <font color="blue">regulations</font> of <font color="blue">government</font>     agencies such as <font color="blue">the FDA We </font>have <font color="blue">implemented quality assurance</font> and other     systems that are intended to comply with applicable <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Although we believe that we have <font color="blue">adequate processes</font> in place to ensure     <font color="blue">compliance with</font> these <font color="blue">requirements</font>, the FDA or other <font color="blue">regulatory bodies</font> could     force us to <font color="blue">stop <font color="blue">manufacturing</font></font> or selling our products if                                           19     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>it concludes that we are out of <font color="blue">compliance with</font> applicable <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The     FDA and other <font color="blue">regulatory bodies</font> could also require us to <font color="blue">recall products</font> if     we fail to comply with applicable <font color="blue">regulations</font>, <font color="blue">which could</font> force us to stop     <font color="blue">manufacturing</font>  such  products</td>
    </tr>
    <tr>
      <td>See  the  Section entitled “Government     Regulation” in Item 1 of this <font color="blue">Annual Report </font>for a further discussion of     applicable regulatory <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Risks Relating to Our Industry, Business and Strategy          <font color="blue">Our Ability </font>to Sell Products Could be <font color="blue">Affected </font>by <font color="blue">Competition From New </font>and     Existing  Diagnostic Products and by Treatment or Other Non-Diagnostic     Products Which May be Developed</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">diagnostic</font> industry</font> is <font color="blue">focused on</font> the testing of <font color="blue">biological specimens</font> in     a <font color="blue">laboratory</font> or at the point of care and is <font color="blue">highly competitive</font> and rapidly     changing</td>
    </tr>
    <tr>
      <td>Many of our principal <font color="blue">competitors</font> have <font color="blue">considerably</font> greater     financial, technical and marketing resources</td>
    </tr>
    <tr>
      <td>As <font color="blue"><font color="blue">new products</font> enter</font> the     market, our <font color="blue">products may become obsolete</font> or a competitor’s products may be     more <font color="blue">effective</font> or more <font color="blue">effective</font>ly marketed and <font color="blue">sold than ours</font></td>
    </tr>
    <tr>
      <td>If we fail     to maintain and enhance our <font color="blue">competitive position</font>, our <font color="blue">customers may decide</font>     to <font color="blue">use products</font> developed by <font color="blue">competitors</font> <font color="blue">which could</font> result in a loss of     revenues</td>
    </tr>
    <tr>
      <td>We <font color="blue">also face <font color="blue">competition</font> from products which may</font> be sold at a lower price</td>
    </tr>
    <tr>
      <td>To the extent this <font color="blue">competition</font> arises, customers may choose to buy lower     cost products from <font color="blue">third parties</font> or we may be forced to sell our products at     a lower price, both of <font color="blue">which could</font> result in a loss of revenues or a lower     gross <font color="blue">margin contribution from</font> the sale of our products</td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">development</font> and <font color="blue">commercialization</font> of products outside of the <font color="blue"><font color="blue">diagnostic</font>s</font>     <font color="blue">industry could <font color="blue"><font color="blue">adversely</font> affect</font> sales</font> of our product</td>
    </tr>
    <tr>
      <td>For example, the     <font color="blue">development</font> of a safe and <font color="blue">effective</font> vaccine to HIV or <font color="blue">treatments</font> for other     diseases or <font color="blue">conditions</font> that our products are designed to detect, could     reduce, or <font color="blue">eventually eliminate</font>, the demand for our HIV or other <font color="blue">diagnostic</font>     products and thereby result in a loss of revenues</td>
    </tr>
    <tr>
      <td>In  order  to <font color="blue">remain competitive</font>, we <font color="blue">must regularly commit</font> substantial     resources to research and <font color="blue">development</font> and the <font color="blue">commercialization</font> of new     products</td>
    </tr>
    <tr>
      <td>The research and <font color="blue">development</font> process <font color="blue">generally</font> takes a <font color="blue">significant</font> amount of     time <font color="blue">from inception</font> to <font color="blue">commercial product launch</font></td>
    </tr>
    <tr>
      <td>This process is conducted     in <font color="blue">various stages</font></td>
    </tr>
    <tr>
      <td>During <font color="blue">each stage there</font> is a substantial risk that we     will not achieve our goals on a <font color="blue">timely basis</font>, or at all, and we may have to     abandon a product in which we have invested substantial amounts</td>
    </tr>
    <tr>
      <td>During 2005, 2004 and 2003, we incurred dlra5dtta3 million, dlra6dtta1 million and dlra8dtta0     million, respectively, in research and <font color="blue">development</font> expenses</td>
    </tr>
    <tr>
      <td>We expect to     continue  to incur <font color="blue">significant</font> costs from our research and <font color="blue">development</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Successful  </font>products  require  <font color="blue">significant</font> <font color="blue">development</font> and <font color="blue">investment</font>,     including testing, to <font color="blue">demonstrate</font> their cost-<font color="blue">effective</font>ness or other benefits     prior  to  <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>In addition, regulatory approval must be     obtained before <font color="blue">most products may</font> be sold</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">development</font> efforts on     these <font color="blue">products will</font> be required before any <font color="blue">regulatory authority</font> will review     them</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">authorities may</font> not approve these products for commercial     sale</td>
    </tr>
    <tr>
      <td>In  addition, even if a product is developed and all applicable     <font color="blue">regulatory approvals</font> are obtained, there may be little or no market for the     product</td>
    </tr>
    <tr>
      <td>Accordingly,  if  we fail to develop <font color="blue">commercially successful</font>     products, or if <font color="blue">competitors</font> develop more <font color="blue">effective</font> products or a greater     number of successful <font color="blue">new products</font>, <font color="blue">customers may decide</font> to <font color="blue">use products</font>     developed by our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>This would result in a loss of revenues and     <font color="blue"><font color="blue">adversely</font> affect</font> our results of <font color="blue">operations</font>, cash flows and business</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________    [47]Table of <font color="blue">Contents       </font>If We Lose Our Key Personnel or Are Unable to Attract and Retain Qualified     Personnel as Necessary, Our Business Could be Harmed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> to a large <font color="blue">extent upon</font> the <font color="blue">contributions</font> of our     executive  officers,  <font color="blue">management</font>, and sales, marketing, <font color="blue">operations</font> and     scientific  staff</td>
    </tr>
    <tr>
      <td>We  may not be able to attract or retain qualified     employees  in  the future due to the intense <font color="blue">competition</font> for qualified     <font color="blue">personnel among <font color="blue">medical products</font> businesses</font></td>
    </tr>
    <tr>
      <td>If  we  are  not able to attract and retain the <font color="blue"><font color="blue">necessary</font> personnel</font> to     accomplish our business <font color="blue">objectives</font>, we may experience <font color="blue">constraints</font> that will     <font color="blue"><font color="blue">adversely</font> affect</font> our ability to <font color="blue">effective</font>ly <font color="blue">manufacture</font>, sell and market our     products, to meet the demands of our <font color="blue">strategic partners</font> in a <font color="blue">timely fashion</font>,     or  to <font color="blue">support internal research</font> and <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>Although we     believe  we  will  be successful in attracting and retaining qualified     personnel, <font color="blue">competition</font> for experienced <font color="blue">scientists</font> and other <font color="blue">personnel from</font>     <font color="blue">numerous companies</font> and academic and other <font color="blue">research institutions may limit</font>     our ability to do so on acceptable terms</td>
    </tr>
    <tr>
      <td>We may from time to time <font color="blue">restructure</font> and <font color="blue">consolidate various aspects</font> of our     <font color="blue">operations</font> in order to achieve <font color="blue">cost savings</font> and other <font color="blue">efficiencies</font></td>
    </tr>
    <tr>
      <td>For     example, during 2004 we completed the <font color="blue">restructuring</font> of our <font color="blue">manufacturing</font>     <font color="blue">operations</font>,  which  included  the transfer of the <font color="blue">manufacturing</font> of our     Intercept^®,  OraSure^®  and oral fluid Western <font color="blue">blot products from</font> our     Beaverton,  Oregon  <font color="blue">facility</font>  and a contract <font color="blue">manufacture</font>r in Oregon to     Bethlehem, Pennsylvania</td>
    </tr>
    <tr>
      <td>We obtained FDA approval to transfer the <font color="blue">operations</font>     to Pennsylvania, and our <font color="blue">Pennsylvania </font><font color="blue">facilities</font> are ISO certified</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>type of transfer and the need to obtain FDA approval and ISO <font color="blue">certification</font>     could  <font color="blue">interfere with</font> or delay our <font color="blue">manufacturing</font> processes and disrupt     continued <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any delay in or <font color="blue">disruption</font> of <font color="blue">operations</font>, and in     particular <font color="blue">manufacturing</font> <font color="blue">operations</font>, could result in <font color="blue">increased costs</font> or     <font color="blue">could delay</font> or <font color="blue">prevent us from selling certain products</font> and thereby result     in a loss of revenue</td>
    </tr>
    <tr>
      <td>We may consider <font color="blue">strategic <font color="blue">acquisition</font>s</font> or <font color="blue">investment</font>s as a way to expand our     business in the future</td>
    </tr>
    <tr>
      <td>These <font color="blue">activities</font>, and their <font color="blue">impact on</font> our business,     are subject to the <font color="blue">following risk factors</font>:           •   Suitable <font color="blue">acquisition</font>s or <font color="blue">investment</font>s may not be found or consummated     on terms that are satisfactory to us;           •   We may be unable to <font color="blue"><font color="blue">successfully</font> integrate</font> an acquired company’s     personnel, assets, <font color="blue">management</font> systems and <font color="blue"><font color="blue">technology</font> into</font> our business;           •   <font color="blue">Acquisitions </font>may require substantial expense and <font color="blue">management</font> time and     could disrupt our business;           •   An <font color="blue">acquisition</font> and subsequent integration <font color="blue">activities</font> may require     <font color="blue">greater capital resources than originally</font> anticipated at the time of     <font color="blue">acquisition</font>;           •   An <font color="blue">acquisition</font> may result in the incurrence of <font color="blue">unexpected expenses</font>,     the dilution of our earnings or our existing <font color="blue">stockholders</font>’ percentage     ownership, or <font color="blue">potential losses from undiscovered <font color="blue">liabilities</font></font> not <font color="blue">covered by</font>     an <font color="blue">indemnification from</font> the seller(s) of the acquired business;           •   An <font color="blue">acquisition</font> may result in the loss of <font color="blue">existing key personnel</font> or     customers or the loss of the acquired company’s key personnel or customers;           •   The benefits expected to be <font color="blue">derived from</font> an <font color="blue">acquisition</font> may not     <font color="blue">materialize</font> and could be affected by <font color="blue">numerous factors</font>, such as regulatory     <font color="blue">development</font>s, general economic <font color="blue">conditions</font> and increased <font color="blue">competition</font>; and           •   An <font color="blue">acquisition</font> of a foreign business <font color="blue">may involve <font color="blue">additional</font> risks</font>,     including, but not limited to, foreign currency exposure, <font color="blue">liability</font> under     <font color="blue">foreign laws</font> or <font color="blue">regulations</font>, and not being able to <font color="blue"><font color="blue">successfully</font> assimilate</font>     <font color="blue">differences</font> in foreign business practices or <font color="blue">overcome language</font> or cultural     barriers</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>The occurrence of one or more of the above or other <font color="blue">factors may prevent us</font>     from achieving all or a <font color="blue">significant</font> part of the benefits expected from an     <font color="blue">acquisition</font>  or  <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>This  may <font color="blue"><font color="blue">adversely</font> affect</font> our financial     condition,  results  of <font color="blue">operations</font> and ability to grow our business or     otherwise achieve our financial or strategic <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our Net Sales Could </font>be <font color="blue">Affected </font>by Third-Party Reimbursement Policies and     <font color="blue">Potential Cost Constraints</font></td>
    </tr>
    <tr>
      <td>The  end-users  of  our  products are expected to <font color="blue">increasingly</font> include     hospitals, physicians and other <font color="blue">healthcare providers</font></td>
    </tr>
    <tr>
      <td>Use of our products     could be <font color="blue">adversely</font> impacted if these end-users do not receive <font color="blue">reimbursement</font>     for the cost of our <font color="blue">products by</font> their patients’ healthcare insurers or     payors</td>
    </tr>
    <tr>
      <td>Our  <font color="blue"><font color="blue">net <font color="blue">sales could</font></font> also</font> be <font color="blue"><font color="blue">adversely</font> affect</font>ed by changes in     <font color="blue">reimbursement</font>  policies  of <font color="blue"><font color="blue">government</font>al</font> or <font color="blue">private healthcare payors</font>,     including in particular the level of <font color="blue">reimbursement</font> for our products</td>
    </tr>
    <tr>
      <td>In the     <font color="blue">United States</font>, <font color="blue">healthcare providers</font> such as hospitals and physicians who     purchase  <font color="blue">diagnostic</font>  products  <font color="blue">generally</font>  rely on third-party payors,     <font color="blue">principally</font>  <font color="blue">private health insurance</font> plans, Medicare and Medicaid, to     reimburse all or part of the cost of the product and procedure</td>
    </tr>
    <tr>
      <td>We believe     that the <font color="blue">overall escalating cost</font> of <font color="blue">medical products</font> and services has led     to, and <font color="blue">will continue</font> to lead to, <font color="blue">increased pressures on</font> the healthcare     industry, both foreign and domestic, to reduce the cost of products and     services</td>
    </tr>
    <tr>
      <td>Given the efforts to control and reduce healthcare costs in the     <font color="blue"><font color="blue">United States</font> </font>in recent years, currently available levels of <font color="blue">reimbursement</font>     may not continue to be available in the future for our <font color="blue">existing products</font> or     products under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">reimbursement</font> and <font color="blue">coverage may</font> not     be available or adequate in either the <font color="blue"><font color="blue">United States</font> </font>or foreign markets,     current <font color="blue">reimbursement</font> amounts may be decreased in the future and future     <font color="blue">legislation</font>, and regulation or <font color="blue">reimbursement</font> policies of third-party payors     may reduce the demand for our products or our ability to sell our products     on a <font color="blue">profitable basis</font></td>
    </tr>
    <tr>
      <td>Increases in Demand for Our Products Could Require Us to Spend Considerable     Resources to Meet the Demand or Harm Our Customer Relationships if We are     <font color="blue">Unable to Meet Demand</font></td>
    </tr>
    <tr>
      <td>If we experience <font color="blue">significant</font> or <font color="blue">unexpected increases</font> in the demand for our     products, we and our <font color="blue">suppliers may</font> not be able to meet that <font color="blue">demand without</font>     expending  <font color="blue"><font color="blue">additional</font> capital resources</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">capital resources could</font>     involve the cost of <font color="blue">new machinery</font> or even the cost of new <font color="blue">manufacturing</font>     <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">would increase</font> our capital costs, <font color="blue">which could</font> <font color="blue">adversely</font>     affect our earnings</td>
    </tr>
    <tr>
      <td>Our <font color="blue">suppliers may</font> be unable or unwilling to expend the     <font color="blue"><font color="blue">necessary</font> capital resources</font> or <font color="blue">otherwise expand</font> their <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>If we or our     suppliers are unable to develop <font color="blue">necessary</font> <font color="blue">manufacturing</font> capabilities in a     timely  manner,  our <font color="blue">net <font color="blue">sales could</font></font> be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>Failure to     cost-<font color="blue">effective</font>ly increase production volumes, if required, or lower than     anticipated yields or production problems <font color="blue">encountered</font> as a result of changes     that  we  or our suppliers make in our <font color="blue">manufacturing</font> processes to meet     increased demand, could result in shipment delays or <font color="blue">interruptions</font> and     increased <font color="blue">manufacturing</font> costs, <font color="blue">which could</font> also have a material adverse     effect on our revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to <font color="blue">meet customer demand</font> for our <font color="blue">products could also harm</font> our     <font color="blue">customer <font color="blue">relationships</font></font> and impair our <font color="blue">reputation within</font> the industry</td>
    </tr>
    <tr>
      <td>This,     in turn, could have a material adverse effect on our business and prospects</td>
    </tr>
    <tr>
      <td>We have marketed many of our <font color="blue">products by</font> collaborating with <font color="blue">laboratories</font>,     <font color="blue">diagnostic</font> companies and <font color="blue"><font color="blue">distributor</font>s</font></td>
    </tr>
    <tr>
      <td>For example, our OraSure^® oral fluid     <font color="blue">collection</font> device is distributed to the insurance industry through major     <font color="blue"><font color="blue">insurance testing</font> <font color="blue">laboratories</font></font>, and <font color="blue">Abbott Laboratories </font>has <font color="blue">exclusive rights</font>     to distribute our OraQuick^® ADVANCE^^™ HIV-1/2 test in the US hospital     market and non-<font color="blue">exclusive rights</font> to the US physicians’ office market</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">sales depend</font> to a substantial <font color="blue">degree on</font> our ability to <font color="blue">sell products</font> to     these customers and develop <font color="blue">new product <font color="blue">distribution channels</font></font>, and on the     <font color="blue">marketing abilities</font> of the <font color="blue">companies with which</font> we <font color="blue">collaborate</font></td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________    [49]Table of <font color="blue">Contents       </font>Some  of  our <font color="blue"><font color="blue">distributor</font>s</font> have <font color="blue">consolidated</font> in recent years, and such     <font color="blue">consolidation</font> has had, and <font color="blue">may continue</font> to have, an adverse <font color="blue">impact on</font> the     level of orders for our products</td>
    </tr>
    <tr>
      <td>One of these <font color="blue">laboratories</font>, LabOne, Inc,     acquired another large insurance <font color="blue">laboratory</font> customer, Osborne Group, Inc,     in 2001 and our revenues decreased because of <font color="blue">efficiencies</font> resulting from     that <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>More recently, LabOne was acquired by another of our     <font color="blue">laboratory</font> <font color="blue"><font color="blue">distributor</font>s</font>, Quest Diagnostics, and this <font color="blue">acquisition</font> could also     affect the level of our revenues</td>
    </tr>
    <tr>
      <td>In  addition,  some <font color="blue"><font color="blue">distributor</font>s</font> have experienced, and <font color="blue">may continue</font> to     experience, <font color="blue">pressure from</font> their customers to reduce the price of their     products and <font color="blue">testing services</font></td>
    </tr>
    <tr>
      <td>For example, several of our <font color="blue">insurance testing</font>     <font color="blue">laboratories</font> are facing this pressure and are using lower cost “home brew”     <font color="blue">insurance testing</font> assays that they have developed <font color="blue">internally</font> or purchased     from our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>This has reduced our <font color="blue">assay sales</font> and is expected to     <font color="blue">lower sales</font> of these products in 2006 and beyond</td>
    </tr>
    <tr>
      <td>Finally,  some  of  our <font color="blue"><font color="blue">distributor</font>s</font> may not fulfill their <font color="blue">contractual</font>     <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>Although we will try to maintain and expand our business with     our  <font color="blue"><font color="blue">distributor</font>s</font>  and  require  that  they  fulfill their <font color="blue">contractual</font>     <font color="blue">obligations</font>, there can be no assurance that such companies <font color="blue">will continue</font> to     purchase or distribute our products, maintain historic order volumes or     otherwise meet their purchase or other <font color="blue">obligations</font>, or that <font color="blue">new distribution</font>     <font color="blue">channels will</font> be <font color="blue">available on</font> satisfactory terms</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently purchase certain critical components</font> of our <font color="blue">products from sole</font>     <font color="blue">supply sources</font></td>
    </tr>
    <tr>
      <td>For example, all of the HIV-1 <font color="blue">antigen used</font> to make our oral     fluid Western blot HIV-1 <font color="blue">confirmatory test</font> is <font color="blue">purchased from</font> BMX, and all of     the HIV antigen and <font color="blue">nitrocellulose</font> required to make our OraQuick^® rapid     HIV-1  <font color="blue">antibody test</font> is <font color="blue">purchased from</font> sole source suppliers</td>
    </tr>
    <tr>
      <td>If these     suppliers are unable or unwilling to supply the required component, we would     need to find another source, and perform <font color="blue">additional</font> <font color="blue">development</font> work and     obtain FDA or other <font color="blue">regulatory approvals</font> for the use of the <font color="blue">alternative</font>     component for our products</td>
    </tr>
    <tr>
      <td><font color="blue">Completing </font>that <font color="blue">development</font> and obtaining such     <font color="blue">approvals could</font> require <font color="blue">significant</font> time to complete and may not occur at     all</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> of critical components from sole <font color="blue">supply sources</font> could     also reduce our control over pricing, quality and <font color="blue">timely delivery</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">events could either disrupt</font> our ability to <font color="blue">manufacture</font> and <font color="blue">sell certain</font> of     our products, or <font color="blue">completely prevent us from</font> doing so or increase our costs</td>
    </tr>
    <tr>
      <td>Any  <font color="blue">such event could</font> have a material adverse effect on our results of     <font color="blue">operations</font>, cash flows and business</td>
    </tr>
    <tr>
      <td>In testing an oral fluid sample <font color="blue">collected with</font> an OraSure^® device for HIV-1     in  the  <font color="blue">United States</font>, our <font color="blue">customers must use</font> an HIV-1 <font color="blue">screening test</font>     <font color="blue">approved by</font> the FDA for use with our OraSure^® device</td>
    </tr>
    <tr>
      <td>Where an oral fluid     sample screens positive for HIV-1, our <font color="blue">customers must then use</font> our oral     fluid Western blot HIV-1 <font color="blue">confirmatory test</font>, which has also <font color="blue">been approved</font> by     the  FDA  for  use with our OraSure^® device, to confirm that positive     <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>BMX <font color="blue">manufacture</font>s and sells the <font color="blue">only oral fluid</font> HIV-1 <font color="blue">screening test</font> that has     received FDA approval for use in detecting HIV-1 in an oral fluid specimen     <font color="blue">collected with</font> our OraSure^® <font color="blue">collection</font> device</td>
    </tr>
    <tr>
      <td>BMX has developed a new     HIV-1 <font color="blue">screening test</font>, and has indicated that this <font color="blue">new test will eventually</font>     replace its existing FDA-approved HIV-1 <font color="blue">screening test</font></td>
    </tr>
    <tr>
      <td>We are working with     BMX  to obtain FDA approval for use of the new <font color="blue">screening test</font> with our     OraSure^® device and expect BMX to file a submission for approval with the     FDA during 2006</td>
    </tr>
    <tr>
      <td>BMX <font color="blue">also supplies</font> the HIV-1 <font color="blue">antigen used</font> to <font color="blue">manufacture</font> our     oral  fluid  Western blot HIV-1 <font color="blue">confirmatory test</font> and is the exclusive     world-wide <font color="blue">distributor</font> of that product</td>
    </tr>
    <tr>
      <td>If BMX ceases to <font color="blue">manufacture</font> or sell an HIV-1 <font color="blue">screening test</font> <font color="blue">approved by</font> the     FDA for use with our OraSure^® <font color="blue">collection</font> device, or if our oral fluid     Western blot HIV-1 <font color="blue">confirmatory test</font> is not made available to our                                           23     ______________________________________________________________________    [50]Table of <font color="blue">Contents       </font>customers (because BMX <font color="blue">either fails</font> to supply the HIV-1 antigen required to     make this product or fails to distribute this product), we would need to     <font color="blue">find alternate suppliers</font> for these products, which would require <font color="blue">additional</font>     <font color="blue">development</font> work and FDA approval</td>
    </tr>
    <tr>
      <td>These <font color="blue">activities</font> would likely require     <font color="blue">significant</font>  time to complete</td>
    </tr>
    <tr>
      <td>If our <font color="blue">customers cannot</font> obtain an HIV-1     screening  test  or Western blot HIV-1 <font color="blue">confirmatory test</font> that has been     <font color="blue">approved by</font> the FDA for use in <font color="blue">connection</font> with our OraSure^® <font color="blue">collection</font>     device, these <font color="blue">customers would likely stop purchasing</font> our OraSure^® device</td>
    </tr>
    <tr>
      <td>Sales of the OraSure^® device were dlra10dtta0 million and dlra11dtta0 million, or 14prca     and 20prca of our <font color="blue">total revenues</font>, in 2005 and 2004, respectively</td>
    </tr>
    <tr>
      <td>Although we intend to pursue some <font color="blue">product <font color="blue">opportunities</font> in<font color="blue">dependent</font>ly</font>,     <font color="blue">opportunities</font> that require a <font color="blue">significant</font> level of <font color="blue">investment</font> for <font color="blue">development</font>     and <font color="blue">commercialization</font> or a <font color="blue">distribution network beyond</font> our <font color="blue">existing sales</font>     <font color="blue">force may necessitate involving one</font> or more <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>Our strategy     for <font color="blue">development</font> and <font color="blue">commercialization</font> of <font color="blue">products may entail entering into</font>     arrangements with <font color="blue"><font color="blue">distributor</font>s</font> or other corporate partners, universities,     research <font color="blue">laboratories</font>, licensees and others</td>
    </tr>
    <tr>
      <td>We may be required to transfer     material rights to such <font color="blue">strategic partners</font>, licensees and others</td>
    </tr>
    <tr>
      <td>While we     expect that our current and future partners, licensees and others have and     will have an <font color="blue">economic motivation</font> to succeed in performing their <font color="blue">contractual</font>     responsibilities, there is no assurance that they will do so and the amount     and timing of resources to be devoted to these <font color="blue">activities</font> will be controlled     by others</td>
    </tr>
    <tr>
      <td>Consequently, there can be no assurance that any revenues or     <font color="blue">profits will</font> be <font color="blue">derived from</font> such arrangements</td>
    </tr>
    <tr>
      <td>We achieved our first full year of <font color="blue">profitability</font> in 2005, when we recorded     net income of dlra27dtta4 million, which includes a dlra17dtta7 million net income tax     benefit</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, the Company had an <font color="blue">accumulated deficit</font> of     dlra103dtta7 million</td>
    </tr>
    <tr>
      <td>Our  ability  to achieve continued <font color="blue">profitability</font> in the <font color="blue">future will</font> be     <font color="blue">dependent</font>  upon a number of factors including, <font color="blue">without <font color="blue">limitation</font></font>, the     following:           •   Creating <font color="blue">market <font color="blue">acceptance</font></font> for and selling increasing volumes of our     OraQuick^® ADVANCE^™ rapid HIV-1/2 <font color="blue">antibody test</font>, Intercept^® <font color="blue">drug testing</font>     product, and OraSure^® <font color="blue">collection</font> device;           •   The degree to which certain of our <font color="blue">new products</font> may replace sales of     our <font color="blue">existing products</font> and the <font color="blue">financial impact</font> of that change, including the     degree to which our OraQuick^® ADVANCE^™ <font color="blue">test will replace</font> our OraSure^®     <font color="blue">collection</font> device for HIV-1 testing or sales of our <font color="blue">cryosurgical wart</font>     <font color="blue">removal products</font> in the OTC <font color="blue">market will replace sales</font> of our Histofreezer^®     product to physicians’ offices or other <font color="blue">professional markets</font>;           •   <font color="blue">Achieving </font>growth in sales of our wart <font color="blue">removal products</font> in the OTC     market and selling other products, such as our OraQuick^® ADVANCE^™ test, in     the OTC market;           •   <font color="blue">Achieving </font>growth in <font color="blue">international</font> markets with our OraQuick^®     ADVANCE^™ test, <font color="blue">cryosurgical wart</font> <font color="blue">removal products</font> and other products;           •   Changes in the level of <font color="blue">competition</font>, such as would occur if larger and     financially stronger <font color="blue">competitors</font> introduced new or <font color="blue">lower priced products</font> to     <font color="blue">compete with</font> our products;           •   Changes in economic <font color="blue">conditions</font> in domestic or <font color="blue">international</font> markets,     such as economic downturns, reduced demand, inflation and currency     <font color="blue">fluctuations</font>;           •   Failure to achieve our targets for growth in revenues;                                           24     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font>  •   Changes in <font color="blue">distributor</font> buying patterns or a buildup of <font color="blue">significant</font>     quantities in our <font color="blue"><font color="blue">distributor</font>s</font>’ inventories or <font color="blue">distribution channels</font>; and           •   Commercially developing, and obtaining <font color="blue">regulatory approvals</font> and     creating <font color="blue">market <font color="blue">acceptance</font></font> for <font color="blue">new products</font> in a time <font color="blue">frame consistent with</font>     our <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>Even though we achieved <font color="blue">profitability</font> for 2005, there can be no assurance     that we will be able to sustain such <font color="blue">profitability</font> in the future</td>
    </tr>
    <tr>
      <td>Utilization of Our Deferred Tax Assets May Be Limited and is <font color="blue">Dependent </font>on     <font color="blue">Future Taxable Income</font></td>
    </tr>
    <tr>
      <td>As  of  <font color="blue">December </font>31,  2005,  we had <font color="blue">federal net</font> operating loss (“NOL”)     <font color="blue">carryforwards</font> of dlra66dtta6 million for <font color="blue">federal income tax purposes</font></td>
    </tr>
    <tr>
      <td>The Tax     Reform Act of 1986 contains provisions under Section 382 of the Internal     Revenue Code that limit the NOLs that may be used in any <font color="blue">given year</font> in the     event of <font color="blue">specified occurrences</font>, including <font color="blue">significant</font> ownership changes</td>
    </tr>
    <tr>
      <td>If     these <font color="blue">specified events</font> occur, we may lose some or all of the <font color="blue">tax benefits</font> of     these <font color="blue">carryforwards</font></td>
    </tr>
    <tr>
      <td>During 2005, we determined, <font color="blue">based on</font> our <font color="blue">assessment</font> of both positive and     <font color="blue">negative evidence</font>, which takes <font color="blue">into consideration</font> our <font color="blue">forecasted taxable</font>     income, that it was more <font color="blue">likely than</font> not that we <font color="blue">will benefit from</font> the use     of  a <font color="blue">significant</font> portion of our <font color="blue">deferred tax assets</font>, and therefore we     reduced our <font color="blue"><font color="blue">valuation allowance</font> on</font> our <font color="blue">deferred tax assets</font> related to these     NOLs</td>
    </tr>
    <tr>
      <td>Upon reducing the <font color="blue">valuation allowance</font>, we recognized dlra26dtta7 million of     <font color="blue">deferred tax assets</font> of which dlra18dtta2 million was recognized as a non-cash tax     benefit  and  dlra8dtta5  million  was  recorded  <font color="blue">directly as</font> an increase in     <font color="blue">stockholders</font>’ equity</td>
    </tr>
    <tr>
      <td>The favorable impact of the <font color="blue">tax benefit distorts</font> the     trends in our operating results and impacts the <font color="blue">comparability</font> of our current     period  results  of <font color="blue">operations</font> with other periods</td>
    </tr>
    <tr>
      <td>If in the future we     determine, <font color="blue">based on</font> our <font color="blue">assessment</font> of both positive and <font color="blue">negative evidence</font>,     that it is more <font color="blue">likely than</font> not that we will not realize all or a portion of     the  deferred  tax assets, we will record a <font color="blue"><font color="blue">valuation allowance</font> on</font> the     <font color="blue">deferred tax assets</font> which would result in <font color="blue">recognition</font> of <font color="blue">income tax expense</font></td>
    </tr>
    <tr>
      <td>We May Require Future <font color="blue">Additional </font>Capital</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future liquidity</font> and ability to meet our future capital <font color="blue">requirements</font>     will  depend  on  <font color="blue">numerous factors</font>, including, but not limited to, the     following:           •   The costs and timing of the expansion of our <font color="blue">manufacturing</font> <font color="blue">capacity</font>;           •   The success of our research and product <font color="blue">development</font> efforts;           •   The magnitude of <font color="blue">capital expenditures</font>;           •   Changes in existing and potential <font color="blue">relationships</font> with business     partners;           •   The time and cost of obtaining <font color="blue">regulatory approvals</font>;           •   The <font color="blue">costs involved</font> in obtaining and enforcing patents, proprietary     rights and <font color="blue"><font color="blue">necessary</font> licenses</font>;           •   The costs and <font color="blue"><font color="blue">liability</font> associated with patent <font color="blue">infringement</font></font> or other     types of <font color="blue">litigation</font>;           •   The costs and timing of expansion of sales and marketing <font color="blue">activities</font>;           •   The timing of the <font color="blue">commercial launch</font> of <font color="blue">new products</font>;           •   The extent to <font color="blue">which existing</font> and <font color="blue">new products</font> gain <font color="blue">market <font color="blue">acceptance</font></font>;           •   The scope and results of <font color="blue">clinical testing</font>;           •   <font color="blue">Competing </font><font color="blue">technological</font> and market <font color="blue">development</font>s; and           •   The scope and timing of <font color="blue">strategic <font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">additional</font> financing is needed, we may seek to <font color="blue">raise funds through</font> the     sale of equity or other securities or <font color="blue">through bank borrowings</font></td>
    </tr>
    <tr>
      <td>There can be     no assurance that <font color="blue">financing through</font> the sale of securities, bank borrowings     or otherwise, will be available to us on satisfactory terms, if at all</td>
    </tr>
    <tr>
      <td>Changes in economic <font color="blue">conditions</font> could <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>For     example, in a <font color="blue">difficult</font> economic environment, customers may be unwilling or     unable to invest in new <font color="blue">diagnostic</font> products, may elect to reduce the amount     of their purchases or may perform less <font color="blue">drug testing</font> because of declining     <font color="blue">employment</font>  levels or the issuance of <font color="blue">fewer life insurance policies</font></td>
    </tr>
    <tr>
      <td>A     weakening business <font color="blue">climate could also</font> cause <font color="blue">longer sales cycles</font> and slower     growth, and <font color="blue">could expose us</font> to increased business or credit risk in dealing     <font color="blue">with customers</font> or suppliers <font color="blue"><font color="blue">adversely</font> affect</font>ed by economic <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Terrorist </font><font color="blue">attacks such as</font> those occurring on <font color="blue">September </font>11, 2001, or national     <font color="blue">disasters such as</font> Hurricane Katrina, and subsequent <font color="blue"><font color="blue">government</font>al</font> responses     to  these events could cause economic <font color="blue">instability</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">actions could</font>     <font color="blue"><font color="blue">adversely</font> affect</font> economic <font color="blue">conditions</font> both within and outside the United     States and reduce demand for our products</td>
    </tr>
    <tr>
      <td><font color="blue">Terrorist </font>attacks and natural     <font color="blue">disasters could</font> cause <font color="blue">government</font>s and regulatory agencies, such as the FDA     or agencies that perform similar functions outside the <font color="blue">United States</font>, to     focus their resources on other matters, such as relief efforts or vaccines     or other <font color="blue">products intended</font> to address the threat of biological or chemical     warfare</td>
    </tr>
    <tr>
      <td>This diversion of <font color="blue">resources could eliminate</font> or delay the bulk     <font color="blue">procurement</font> of our <font color="blue">products by</font> <font color="blue">government</font> agencies or delay our ability to     obtain <font color="blue">regulatory approvals</font> required to <font color="blue">manufacture</font>, market or sell our     products in the <font color="blue"><font color="blue">United States</font> </font>and other countries</td>
    </tr>
    <tr>
      <td>These <font color="blue">events could also</font>     disrupt the <font color="blue">operations</font> of our customers and suppliers and eliminate, reduce     or delay our customers’ ability to purchase and use our products and our     suppliers’ ability to <font color="blue">provide raw materials</font> and finished products</td>
    </tr>
    <tr>
      <td><font color="blue">Our Stock Price Could Continue </font>to be Volatile</td>
    </tr>
    <tr>
      <td>Our stock price has been volatile, has <font color="blue">fluctuated substantially</font> in the past     and may be volatile in the future and could experience substantial declines</td>
    </tr>
    <tr>
      <td>The following factors, among others, could have a <font color="blue">significant</font> <font color="blue">impact on</font> the     market for our <font color="blue">Common Stock</font>:           •   Future <font color="blue"><font color="blue">announcement</font>s concerning</font> us or our products;           •   Future <font color="blue"><font color="blue">announcement</font>s concerning</font> our <font color="blue">competitors</font> or industry;           •   <font color="blue">Developments </font>in patent or other <font color="blue">proprietary rights</font>;           •   <font color="blue">Litigation </font>or threatened <font color="blue">litigation</font>;           •   Public concern as to the performance or safety of products that we or     others have developed or sold;           •   Failure to achieve, or changes in, financial estimates by securities     analysts and comments or opinions about us by securities analysts or major     <font color="blue">stockholders</font>;           •   <font color="blue">Governmental </font>regulation;           •   Clinical results <font color="blue">with respect</font> to our products in <font color="blue">development</font> or those     of our <font color="blue">competitors</font>;           •   Changes in the level of <font color="blue">competition</font>;           •   Loss of or declines in sales to major <font color="blue"><font color="blue">distributor</font>s</font> or customers;           •   The <font color="blue"><font color="blue">relatively</font> low trading volume</font> for our <font color="blue">Common Stock</font>;           •   Period to period <font color="blue">fluctuations</font> in our operating results;           •   General market and economic <font color="blue">conditions</font>; and           •   <font color="blue">Terrorist </font>attacks, civil unrest, war and <font color="blue">national disasters</font></td>
    </tr>
    <tr>
      <td><font color="blue">Future Sales </font>by Existing Stockholders, Executive Officers or Directors Could     Depress the Market Price of Our <font color="blue"><font color="blue">Common Stock</font> </font>and Make It More Difficult For     Us to Sell Stock in the Future</td>
    </tr>
    <tr>
      <td>Sales of our <font color="blue"><font color="blue">Common Stock</font> </font>in the <font color="blue">public market</font>, or the <font color="blue">perception</font> that such     <font color="blue">sales could</font> occur, <font color="blue">could negatively impact</font> the <font color="blue">market price</font> of our Common     Stock</td>
    </tr>
    <tr>
      <td>We are unable to estimate the number of shares of our                                           26     ______________________________________________________________________    [53]Table of <font color="blue">Contents       </font><font color="blue"><font color="blue">Common Stock</font> </font>that <font color="blue">may actually</font> be resold in the <font color="blue">public market</font> since this     will  depend  on the <font color="blue">market price</font> for our <font color="blue">Common Stock</font>, the individual     <font color="blue">circumstances</font> of the sellers and other factors</td>
    </tr>
    <tr>
      <td>We have a number of institutional <font color="blue">stockholders</font> that own <font color="blue">significant</font> blocks     of  our  <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>If one or more of these <font color="blue">stockholders</font> sell large     portions of their holdings in a <font color="blue">relatively</font> short time, for liquidity or     other reasons, the prevailing <font color="blue">market price</font> of our <font color="blue"><font color="blue">Common Stock</font> </font>could be     <font color="blue">negatively affected</font></td>
    </tr>
    <tr>
      <td>In addition, it is possible that one or more of our     <font color="blue">executive officers</font> or members of our <font color="blue">Board of Directors </font><font color="blue">could sell shares</font> of     our <font color="blue"><font color="blue">Common Stock</font> </font>during an <font color="blue">open trading window under</font> our Insider Trading     Policy</td>
    </tr>
    <tr>
      <td>These <font color="blue">transactions</font> and the perceived reasons for these <font color="blue">transactions</font>     could have a negative effect on the prevailing <font color="blue">market price</font> of our Common     Stock</td>
    </tr>
    <tr>
      <td><font color="blue">Our Reported Financial Results May </font>be Adversely <font color="blue">Affected </font>by Changes in     Accounting Principles Generally Accepted in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We prepare our <font color="blue">financial statements</font> in <font color="blue">conformity with <font color="blue">accounting</font> principles</font>     <font color="blue">generally</font> accepted in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">accounting</font> principles are     subject to creation or interpretation by the Financial Accounting Standards     Board, the Securities and Exchange Commission and various bodies formed to     interpret and create <font color="blue">appropriate</font> <font color="blue">accounting</font> principles</td>
    </tr>
    <tr>
      <td>A change in these     principles  or  <font color="blue">interpretations could</font> have a <font color="blue">significant</font> effect on our     reported financial results, and <font color="blue">could affect</font> the reporting of <font color="blue">transactions</font>     completed before the <font color="blue">announcement</font> of a change</td>
    </tr>
    <tr>
      <td>Risks Relating to Intellectual Property          Our Success Depends on <font color="blue"><font color="blue">Our Ability </font>to Protect Our Proprietary Technology</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">diagnostic</font>s</font> industry places considerable <font color="blue">importance on</font> obtaining patent,     trademark,  and trade secret protection, as well as other <font color="blue">intellectual</font>     <font color="blue">property rights</font>, for new <font color="blue">technologies</font>, products and processes</td>
    </tr>
    <tr>
      <td>Our success     depends,  in  part,  on  our  ability to develop and maintain a strong     <font color="blue">intellectual</font> property portfolio or obtain licenses to patents for products     and <font color="blue"><font color="blue">technologies</font> both</font> in the <font color="blue"><font color="blue">United States</font> </font>and in other countries</td>
    </tr>
    <tr>
      <td>As <font color="blue">appropriate</font>, we intend to file patent <font color="blue">application</font>s and obtain patent     protection for our <font color="blue">proprietary <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>These patent <font color="blue">application</font>s and     patents will cover, as applicable, compositions of matter for our products,     methods of making those products, methods of using those products, and     apparatus relating to the use or <font color="blue">manufacture</font> of those products</td>
    </tr>
    <tr>
      <td>We will also     rely on <font color="blue">trade secrets</font>, know-how, and continuing <font color="blue">technological</font> advancements     to protect our <font color="blue">proprietary <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>We have entered, and <font color="blue">will continue</font> to enter, into confidentiality <font color="blue"><font color="blue">agreement</font>s</font>     with our employees, consultants, advisors and <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>However, these     parties  may  not  honor  these  <font color="blue"><font color="blue">agreement</font>s</font>  and we may not be able to     <font color="blue"><font color="blue">successfully</font> protect</font> our rights to <font color="blue">unpatented <font color="blue">trade secrets</font></font> and know-how</td>
    </tr>
    <tr>
      <td>Others  may in<font color="blue">dependent</font>ly develop <font color="blue">substantially equivalent proprietary</font>     information and <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to our <font color="blue">trade secrets</font> and     know-how</td>
    </tr>
    <tr>
      <td>Many of our employees, including scientific and <font color="blue">management</font> personnel, were     <font color="blue">previously</font> employed by competing companies</td>
    </tr>
    <tr>
      <td>Although we encourage and expect     all of our employees to <font color="blue">abide by</font> any <font color="blue">confidentiality <font color="blue">agreement</font> with</font> a prior     employer, competing companies may allege <font color="blue">trade secret violations</font> and similar     claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>We may <font color="blue">collaborate</font> with universities and <font color="blue"><font color="blue">government</font>al</font> research organizations     which, as a result, may acquire part of the rights to any <font color="blue">inventions</font> or     technical information <font color="blue">derived from</font> collaboration with them</td>
    </tr>
    <tr>
      <td>To facilitate <font color="blue">development</font> and <font color="blue">commercialization</font> of a <font color="blue">proprietary <font color="blue">technology</font></font>     base, we may need to obtain licenses to patents or other <font color="blue">proprietary rights</font>     from other parties</td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining </font>and maintaining such licenses may                                           27     ______________________________________________________________________    [54]Table of <font color="blue">Contents       </font>require the payment of substantial amounts</td>
    </tr>
    <tr>
      <td>In addition, if we are unable to     obtain   these   types   of  licenses,  our  product  <font color="blue">development</font>  and     <font color="blue">commercialization</font> efforts may be delayed or precluded</td>
    </tr>
    <tr>
      <td>We  may  incur substantial costs and be required to expend substantial     resources in asserting or protecting our <font color="blue">intellectual</font> <font color="blue">property rights</font>, or in     defending suits <font color="blue">against us</font> related to <font color="blue">intellectual</font> <font color="blue">property rights</font></td>
    </tr>
    <tr>
      <td><font color="blue">Disputes     </font>regarding <font color="blue">intellectual</font> <font color="blue">property rights</font> could substantially delay product     <font color="blue">development</font> or <font color="blue">commercialization</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Disputes regarding <font color="blue">intellectual</font>     <font color="blue">property rights</font> might include state, federal or foreign court <font color="blue">litigation</font> as     well  as patent interference, patent reexamination, patent reissue, or     <font color="blue">trademark opposition <font color="blue">proceedings</font></font> in the <font color="blue"><font color="blue">United States</font> </font>Patent and Trademark     Office</td>
    </tr>
    <tr>
      <td><font color="blue">Opposition </font>or revocation <font color="blue">proceedings</font> could be instituted in a     <font color="blue">foreign patent office</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse decision</font> in any proceeding regarding     <font color="blue">intellectual</font> <font color="blue">property rights</font> could result in the loss or <font color="blue">limitation</font> of our     rights to a patent, an invention or trademark</td>
    </tr>
    <tr>
      <td>We are Involved in Pending, and May Become Involved in Future, Intellectual     Property  Infringement  Disputes,  Which are <font color="blue">Costly and Could Limit </font>or     Eliminate  Our  Ability  to  Sell  Our  Products or Use Certain of Our     Technologies in the Future</td>
    </tr>
    <tr>
      <td>From time to time, we may seek to enforce our patents or other <font color="blue">intellectual</font>     <font color="blue">property rights</font> through <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>In addition, there are a large number of     patents and patent <font color="blue">application</font>s in our <font color="blue">product areas</font>, and <font color="blue">additional</font> patents     may be issued to <font color="blue">third parties</font> relating to our <font color="blue">product areas</font></td>
    </tr>
    <tr>
      <td>We may be sued     for  <font color="blue">infringement</font> of patents or <font color="blue">misappropriation</font> of other <font color="blue">intellectual</font>     <font color="blue">property rights</font> <font color="blue">with respect</font> to one or more of our products</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>in     our industry regarding patent and other <font color="blue">intellectual</font> <font color="blue">property rights</font> is     prevalent and is expected to continue</td>
    </tr>
    <tr>
      <td>Our involvement in <font color="blue">litigation</font> <font color="blue">with respect</font> to patents or other <font color="blue">intellectual</font>     property or to determine rights in <font color="blue">proprietary <font color="blue">technology</font></font>, either as a     plaintiff or defendant, could <font color="blue"><font color="blue">adversely</font> affect</font> our revenues, market share,     results of <font color="blue">operations</font> and business because:           •   As is common with major <font color="blue">litigation</font>, it <font color="blue">could consume</font> a substantial     portion of managerial and <font color="blue">financial resources</font>;           •   Its outcome would be uncertain and a <font color="blue">court may find</font> that our patents     are invalid or unenforceable in response to claims by another party or that     the third-party patent claims are valid and <font color="blue">infringed by</font> our products;           •   An <font color="blue">adverse outcome could</font> subject us to the loss of the protection of     our patents or to <font color="blue">liability</font> in the form of past royalty payments, penalties,     special and <font color="blue">punitive damages</font>, or future royalty payments <font color="blue">significant</font>ly     <font color="blue">affecting</font> our <font color="blue">future earnings</font>;           •   Failure to obtain a <font color="blue">necessary</font> license upon an <font color="blue">adverse outcome could</font>     prevent us from selling our current products or other products we may     develop; and           •   A <font color="blue">court could award</font> a preliminary and/or permanent injunction which     <font color="blue">would prevent us from selling</font> our current or <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>The Sales Potential for OraQuick^® Could be <font color="blue">Affected </font>by <font color="blue">Our Ability </font>to     <font color="blue">Obtain Certain Licenses</font></td>
    </tr>
    <tr>
      <td>Our OraQuick^® test is a <font color="blue">lateral flow assay</font> device that tests for specific     <font color="blue">antibodies</font> or other substances</td>
    </tr>
    <tr>
      <td>The term “lateral flow” <font color="blue">generally</font> refers to     a test strip through which a sample flows and <font color="blue">which provides</font> a test result     on a portion of the <font color="blue">strip downstream from</font> where the sample is applied</td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>are <font color="blue">numerous patents</font> in the <font color="blue"><font color="blue">United States</font> </font>and other <font color="blue">countries which</font> claim     <font color="blue">lateral flow assay</font> methods and devices</td>
    </tr>
    <tr>
      <td>Some of these patents may broadly     cover the <font color="blue">technology</font> used in the OraQuick^® test and are in force in the     <font color="blue"><font color="blue">United States</font> </font>and other countries</td>
    </tr>
    <tr>
      <td>We may not be able to make or sell the     OraQuick^® test in the <font color="blue"><font color="blue">United States</font> </font>or other countries where these patents     are in force</td>
    </tr>
    <tr>
      <td>We have obtained <font color="blue">licenses under</font> several lateral flow patents, which we     believe should be sufficient to permit the <font color="blue">manufacturing</font> and sale of the     OraQuick^® device <font color="blue">as currently</font> contemplated</td>
    </tr>
    <tr>
      <td>However, <font color="blue">licenses under</font>                                           28     ______________________________________________________________________    [55]Table of <font color="blue">Contents       </font><font color="blue">additional</font> patents may be required and it is possible that a <font color="blue">third party</font>     could seek to <font color="blue">enforce one</font> or more lateral flow patents <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>In the     event that we are unable to <font color="blue">successfully</font> defend against such <font color="blue">litigation</font> or     it  is determined that a license is required and it is not possible to     negotiate or otherwise obtain a license <font color="blue">agreement</font> on reasonable terms under     a <font color="blue">necessary</font> patent, our ability to <font color="blue">manufacture</font> and sell the OraQuick^®     device  could  be  limited</td>
    </tr>
    <tr>
      <td>In such case, we may be able to modify the     OraQuick^® test such that a <font color="blue">license would</font> not be <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>However, this     <font color="blue">alternative</font> <font color="blue">could delay</font> or limit our ability to sell the OraQuick^® test in     the  <font color="blue"><font color="blue">United States</font> </font>and other markets, which would <font color="blue"><font color="blue">adversely</font> affect</font> our     results of <font color="blue">operations</font>, cash flows and business</td>
    </tr>
    <tr>
      <td>Our future <font color="blue">success will depend</font>, in part, on the <font color="blue">market <font color="blue">acceptance</font></font>, and the     timing  of  such  <font color="blue">acceptance</font>,  of  our <font color="blue">products such as</font> the OraQuick^®     ADVANCE^™ rapid HIV-1/2 <font color="blue">antibody test</font>, the Intercept^® drug test, and other     <font color="blue">new products</font> or <font color="blue">technologies</font> that may be developed or acquired</td>
    </tr>
    <tr>
      <td>To achieve     <font color="blue">market <font color="blue">acceptance</font></font>, we must make substantial <font color="blue">marketing efforts</font> and spend     <font color="blue">significant</font>  funds to <font color="blue">inform potential customers</font> and the public of the     perceived benefits of these products</td>
    </tr>
    <tr>
      <td>There may be limited <font color="blue">evidence on which</font>     to evaluate the market reaction to products that may be developed, and there     can be no assurance that any <font color="blue">products will</font> obtain <font color="blue">market <font color="blue">acceptance</font></font> and fill     the market need that is perceived to exist</td>
    </tr>
    <tr>
      <td>We  have made <font color="blue">significant</font> progress in gaining <font color="blue">acceptance</font> of oral fluid     testing for HIV in the insurance and <font color="blue">public health markets</font></td>
    </tr>
    <tr>
      <td>We have also     made <font color="blue">significant</font> progress in gaining <font color="blue">acceptance</font> of <font color="blue">oral fluid testing</font> for     drugs  of abuse in the workplace and <font color="blue">criminal justice testing markets</font></td>
    </tr>
    <tr>
      <td>However, the ultimate degree of <font color="blue">acceptance</font> in these markets is uncertain,     and  other  markets may resist the adoption of <font color="blue">oral fluid testing</font> as a     <font color="blue">replacement</font> for other <font color="blue">testing methods</font> in use today</td>
    </tr>
    <tr>
      <td>In addition, certain     state <font color="blue">laws prohibit</font> or restrict the use of <font color="blue">oral fluid testing</font> for drugs of     abuse in <font color="blue">certain markets</font> or the rapid, point-of-care testing for HIV As a     result, there can be no assurance that we will be able to expand the use of     our <font color="blue">oral fluid testing</font> products in these or other markets</td>
    </tr>
    <tr>
      <td>We may be held liable if any of our products, or any <font color="blue">product which</font> is made     with the use or <font color="blue">incorporation</font> of any of our <font color="blue">technologies</font>, causes injury of     any  type  or  is  found  <font color="blue">otherwise unsuitable during product testing</font>,     <font color="blue">manufacturing</font>, marketing, sale or usage</td>
    </tr>
    <tr>
      <td>Although we have obtained product     <font color="blue">liability</font>  insurance,  this  insurance  may  not <font color="blue">fully cover potential</font>     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>As we bring <font color="blue">new products</font> to market, we may need to increase our     product <font color="blue">liability</font> coverage</td>
    </tr>
    <tr>
      <td>We are selling <font color="blue">cryosurgical wart</font> <font color="blue">removal products</font> in the consumer or OTC     market in the <font color="blue">United States</font>, Canada, and Europe</td>
    </tr>
    <tr>
      <td>We expect to expand the OTC     sales of these products to other countries and to <font color="blue">eventually distribute</font>     other types of products, such as our OraQuick^® ADVANCE^™ HIV-1/2 test</td>
    </tr>
    <tr>
      <td>We     believe  the  sale of products in the OTC <font color="blue">market increases</font> the risk of     potential product <font color="blue">liability</font> exposure and the required level of insurance     coverage that we will need to maintain</td>
    </tr>
    <tr>
      <td><font color="blue">Inability </font>to obtain sufficient     insurance coverage at an acceptable cost or otherwise to protect against     potential  product  <font color="blue">liability</font>  claims  could  affect  our  decision to     <font color="blue">commercialize</font> <font color="blue">new products</font> and our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">generally</font> sold with labeling that <font color="blue">contains performance</font>     claims approved or <font color="blue">cleared by</font> the FDA or other <font color="blue">regulators</font></td>
    </tr>
    <tr>
      <td>If our products     fail to perform in <font color="blue">accordance with</font> the <font color="blue">applicable label</font> claims or otherwise     in <font color="blue">accordance with</font> the <font color="blue">expectations</font> or needs of our customers, customers may     switch to a competing                                           29     ______________________________________________________________________    [56]Table of <font color="blue">Contents       </font>product or <font color="blue">otherwise stop using</font> our products, and our <font color="blue">revenues could</font> be     <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>In addition, poor performance by one or more of our     products and <font color="blue">publicity surrounding such performance could</font> have an adverse     effect on our reputation, our <font color="blue">continuing ability</font> to <font color="blue">sell products</font> and the     prevailing <font color="blue">market price</font> of our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>Our  Increasing  <font color="blue">International </font>Presence May be <font color="blue">Affected </font>by Regulatory,     Cultural or Other Restraints</td>
    </tr>
    <tr>
      <td>We  intend to increase revenue <font color="blue">derived from</font> <font color="blue">international</font> sales of our     products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> sales accounted for dlra9dtta5 million or 14prca of total     revenues for 2005, dlra6dtta2 million or 11prca of <font color="blue">total revenues</font> for 2004, and dlra4dtta6     million or 11prca of <font color="blue">total revenues</font> for 2003</td>
    </tr>
    <tr>
      <td>A  number  of  factors  can  slow  or  prevent <font color="blue">international</font> sales, or     <font color="blue">substantially increase</font> the cost of <font color="blue">international</font> sales, including those set     forth below:           •   <font color="blue">Regulatory </font><font color="blue">requirements</font> (including <font color="blue">compliance with</font> applicable customs     <font color="blue">regulations</font>) may slow, limit, or prevent the offering of products in foreign     countries;           •   The un<font color="blue">availability</font> of licenses to <font color="blue">certain patents</font> in force in a     <font color="blue">foreign country which cover</font> our products <font color="blue">may restrict</font> our ability to sell     into that country;           •   The <font color="blue">inability</font> to maintain ISO <font color="blue">certification</font> for our or our     suppliers’ <font color="blue">manufacturing</font> <font color="blue">facilities</font> could preclude, interrupt or delay our     ability to <font color="blue">manufacture</font> products for sale in Europe or other <font color="blue">international</font>     <font color="blue">territories</font>;           •   Our ability to obtain the CE mark on our products in a <font color="blue">timely manner</font>     may preclude or delay our ability to <font color="blue">sell products</font> in the European Union;           •   Cultural and political <font color="blue">differences</font> may make it <font color="blue">difficult</font> to     <font color="blue">effective</font>ly market, sell and gain <font color="blue">acceptance</font> of products in foreign     countries;           •   <font color="blue">Inexperience </font>in <font color="blue">international</font> markets may slow or limit our ability to     <font color="blue">sell products</font> in <font color="blue">foreign countries</font>;           •   Exchange rates, currency <font color="blue">fluctuations</font>, tariffs and other barriers,     <font color="blue">extended payment terms</font> and <font color="blue">dependence on</font> and <font color="blue">difficult</font>ies in managing     <font color="blue">international</font> <font color="blue"><font color="blue">distributor</font>s</font> or <font color="blue">representatives may affect</font> our <font color="blue">revenues even</font>     when <font color="blue">product sales</font> occur;           •   The <font color="blue">creditworthiness</font> of <font color="blue">foreign entities may</font> be <font color="blue">less certain</font> and     foreign accounts receivable <font color="blue">collection</font> may be more <font color="blue">difficult</font>;           •   Economic <font color="blue">conditions</font>, the absence of <font color="blue">available funding sources</font>,     terrorism, civil unrest, war and <font color="blue">natural disasters may slow</font> or limit our     ability to sell our products in <font color="blue">foreign countries</font>;           •   <font color="blue">International </font><font color="blue">markets often</font> have long sales cycles, especially for     sales to <font color="blue">foreign <font color="blue">government</font>s</font>, quasi-<font color="blue"><font color="blue">government</font>al</font> agencies and <font color="blue">international</font>     <font color="blue">public health agencies</font>, thereby delaying or limiting our ability to sell our     products; and           •   We may be at a <font color="blue">disadvantage</font> if <font color="blue">competitors</font> in <font color="blue">foreign countries</font> sell     <font color="blue">competing products at prices at</font> or below such <font color="blue">competitors</font>’ or our cost</td>
    </tr>
    <tr>
      <td>In addition, we have <font color="blue">entered into</font> a contract for the <font color="blue">manufacture</font> and supply     of the OraQuick^® test in Thailand, and the Histofreezer^® and Freeze Off^®     <font color="blue">cryosurgical products</font> are currently <font color="blue">manufacture</font>d in <font color="blue">The Netherlands</font></td>
    </tr>
    <tr>
      <td>We may     enter into <font color="blue"><font color="blue">agreement</font>s</font> to <font color="blue">manufacture</font> other products in <font color="blue">foreign countries</font> as     well</td>
    </tr>
    <tr>
      <td>However, <font color="blue">factors such as economic</font> and political <font color="blue">conditions</font> and foreign     regulatory <font color="blue">requirements</font> may slow or prevent the <font color="blue">manufacture</font> of our products     in countries other than the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Interruption </font>of the supply of our     <font color="blue">products could reduce revenues</font> or cause us to incur <font color="blue">significant</font> <font color="blue">additional</font>     expenses in finding an <font color="blue">alternative</font> source of supply</td>
    </tr>
    <tr>
      <td>In addition, foreign     currency <font color="blue">fluctuations</font> and economic <font color="blue">conditions</font> in <font color="blue">foreign countries</font> could     increase the costs of <font color="blue">manufacturing</font> our products in <font color="blue">foreign countries</font></td>
    </tr>
  </tbody>
</table>